Arcturus Therapeutics (ARCT) Revenue & Revenue Breakdown
Arcturus Therapeutics Revenue Highlights
Latest Revenue (Y)
$157.75M
Latest Revenue (Q)
$41.67M
Main Segment (Y)
Collaboration Revenue
Arcturus Therapeutics Revenue by Period
Arcturus Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $157.75M | -23.33% |
2022-12-31 | $205.75M | 1564.82% |
2021-12-31 | $12.36M | 29.56% |
2020-12-31 | $9.54M | -54.12% |
2019-12-31 | $20.79M | 31.97% |
2018-12-31 | $15.75M | 21.20% |
2017-12-31 | $13.00M | 100.00% |
2016-12-31 | - | 100.00% |
2015-12-31 | - | 100.00% |
2014-12-31 | - | 100.00% |
2013-12-31 | - | 100.00% |
2012-12-31 | - | 100.00% |
2011-12-31 | - | - |
Arcturus Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $41.67M | -9.36% |
2024-06-30 | $45.98M | 41.04% |
2024-03-31 | $32.60M | 15.55% |
2023-12-31 | $28.21M | -34.96% |
2023-09-30 | $43.38M | 353.49% |
2023-06-30 | $9.56M | -88.00% |
2023-03-31 | $79.73M | -50.18% |
2022-12-31 | $160.05M | 1097.17% |
2022-09-30 | $13.37M | -50.66% |
2022-06-30 | $27.09M | 416.65% |
2022-03-31 | $5.24M | -9.49% |
2021-12-31 | $5.79M | 137.75% |
2021-09-30 | $2.44M | 21.79% |
2021-06-30 | $2.00M | -5.92% |
2021-03-31 | $2.13M | -4.96% |
2020-12-31 | $2.24M | -4.07% |
2020-09-30 | $2.33M | 0.47% |
2020-06-30 | $2.32M | -12.24% |
2020-03-31 | $2.65M | -10.85% |
2019-12-31 | $2.97M | -10.55% |
2019-09-30 | $3.32M | -67.32% |
2019-06-30 | $10.15M | 133.40% |
2019-03-31 | $4.35M | -42.59% |
2018-12-31 | $7.58M | 121.36% |
2018-09-30 | $3.42M | 43.46% |
2018-06-30 | $2.39M | 0.80% |
2018-03-31 | $2.37M | -81.79% |
2017-12-31 | $13.00M | 294.36% |
2017-09-30 | $3.30M | -12.36% |
2017-06-30 | $3.76M | 100.00% |
2017-03-31 | - | 100.00% |
2016-12-31 | - | 100.00% |
2016-09-30 | - | 100.00% |
2016-06-30 | - | 100.00% |
2016-03-31 | - | 100.00% |
2015-12-31 | - | 100.00% |
2015-09-30 | - | 100.00% |
2015-06-30 | - | 100.00% |
2015-03-31 | - | 100.00% |
2014-12-31 | - | 100.00% |
2014-09-30 | - | 100.00% |
2014-06-30 | - | 100.00% |
2014-03-31 | - | 100.00% |
2013-12-31 | - | 100.00% |
2013-09-30 | - | 100.00% |
2013-06-30 | - | 100.00% |
2013-03-31 | - | 100.00% |
2012-12-31 | - | 100.00% |
2012-09-30 | - | 100.00% |
2012-06-30 | - | - |
Arcturus Therapeutics Revenue Breakdown
Arcturus Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 23 | Dec 22 |
---|---|---|
Collaboration Revenue | $157.75M | $205.75M |
Latest
Quarterly Revenue by Product
Product/Service | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Jun 19 |
---|---|---|---|---|---|---|---|
Grant | $2.86M | $3.88M | $5.41M | $954.00K | $556.00K | - | - |
Collaboration Revenue | $38.81M | $45.98M | $32.60M | $78.02M | $9.56M | $79.73M | - |
Other Collaboration Revenue | - | - | - | - | - | - | $3.60M |
Latest
Arcturus Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
AMLX | Amylyx Pharmaceuticals | $380.79M | $416.00K |
BEAM | Beam Therapeutics | $377.71M | $14.27M |
CRSP | CRISPR Therapeutics | $370.00M | $602.00K |
BPMC | Blueprint Medicines | $249.38M | $128.18M |
ARCT | Arcturus Therapeutics | $157.75M | $41.67M |
ACLX | Arcellx | $110.32M | $26.03M |
FATE | Fate Therapeutics | $63.53M | $6.77M |
NTLA | Intellia Therapeutics | $36.27M | $9.11M |
CRBU | Caribou Biosciences | $34.48M | $3.46M |
STOK | Stoke Therapeutics | $8.78M | $4.89M |
PLRX | Pliant Therapeutics | $1.58M | - |
BDTX | Black Diamond Therapeutics | - | - |
GOSS | Gossamer Bio | - | $9.48M |
DAWN | Day One Biopharmaceuticals | - | $20.07M |
MDGL | Madrigal Pharmaceuticals | - | $62.17M |
BMEA | Biomea Fusion | - | - |
ETNB | 89bio | - | - |
AKRO | Akero Therapeutics | - | - |
FDMT | 4D Molecular Therapeutics | - | - |